BMRN (BioMarin Pharmaceutical Inc.) Stock Financials & Earnings | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

Mkt Cap$12B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$3.2B

Net Income (TTM)$349M

EPS (TTM)$1.80

Free Cash Flow (TTM)$725M

Gross Margin77.1%

Op. Margin16.6%

Net Margin10.8%

FCF Margin22.5%

P/S Ratio (TTM)3.7x

P/E Ratio (TTM)34.1x

YoY Rev Growth+12.9%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$596M	$461M	$62M
Q2 23	$595M	$465M	$66M
Q3 23	$581M	$453M	$31M
Q4 23	$646M	$511M	$14M
Q1 24	$649M	$524M	$88M
Q2 24	$712M	$582M	$120M
Q3 24	$746M	$557M	$114M
Q4 24	$747M	$611M	$161M
Q1 25	$745M	$594M	$224M
Q2 25	$825M	$675M	$277M
Q3 25	$776M	$636M	-$47M
Q4 25	$875M	$579M	$79M

Valuation

Quarter	P/S	P/E
Q1 23	5.5x	166.2x
Q2 23	5.3x	119.1x
Q3 23	5.2x	81.0x
Q4 23	4.9x	71.0x
Q1 24	4.8x	57.9x
Q2 24	4.6x	46.4x
Q3 24	4.3x	36.9x
Q4 24	4.2x	27.9x
Q1 25	4.0x	22.7x
Q2 25	3.9x	18.1x
Q3 25	3.8x	22.9x
Q4 25	3.7x	34.1x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$74M	-$99M
Q2 23	$70M	$47M
Q3 23	$136M	$112M
Q4 23	$27M	-$9M
Q1 24	$47M	$13M
Q2 24	$119M	$97M
Q3 24	$221M	$200M
Q4 24	$186M	$165M
Q1 25	$174M	$158M
Q2 25	$185M	$168M
Q3 25	$369M	$340M
Q4 25	$100M	$59M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$25M
Q2 23	$23M
Q3 23	$23M
Q4 23	$37M
Q1 24	$34M
Q2 24	$22M
Q3 24	$21M
Q4 24	$20M
Q1 25	$17M
Q2 25	$17M
Q3 25	$28M
Q4 25	$41M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+14.8%	+39.8%
Q2 23	+11.5%	+7.1%
Q3 23	+15.0%	+8.5%
Q4 23	+20.2%	+12.4%
Q1 24	+8.8%	+4.9%
Q2 24	+19.6%	+11.7%
Q3 24	+28.3%	+14.7%
Q4 24	+15.6%	-7.3%
Q1 25	+14.8%	-7.0%
Q2 25	+15.9%	-7.3%
Q3 25	+4.1%	+30.2%
Q4 25	+17.0%	+35.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$54M	9.0%
Q2 23	$50M	8.4%
Q3 23	$48M	8.3%
Q4 23	$55M	8.5%
Q1 24	$58M	9.0%
Q2 24	$48M	6.7%
Q3 24	$43M	5.8%
Q4 24	$52M	6.9%
Q1 25	$38M	5.1%
Q2 25	$48M	5.8%
Q3 25	$49M	6.3%
Q4 25	$47M	5.4%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$172M	$105M	$106M
Q2 23	$177M	$91M	$116M
Q3 23	$191M	$51M	$122M
Q4 23	$206M	$142M	$133M
Q1 24	$205M	$107M	$119M
Q2 24	$184M	$140M	$123M
Q3 24	$185M	$145M	$109M
Q4 24	$174M	$141M	$126M
Q1 25	$159M	$104M	$103M
Q2 25	$161M	$110M	$122M
Q3 25	$409M	$137M	$131M
Q4 25	$192M	$802M	—

Revenue Segments

Quarter	Product	Royalty And Other
Q1 24	$638M	$11M
Q2 24	$702M	$10M
Q3 24	$734M	$12M
Q4 24	$736M	$12M
Q1 25	$735M	$11M
Q2 25	$813M	$12M
Q3 25	$761M	$15M
Q4 25	$859M	$15M

Revenue by Geography

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$580M	$572M	$1.2B
Q2 23	$694M	$477M	$1.2B
Q3 23	$785M	$340M	$1.1B
Q4 23	$755M	$319M	$1.1B
Q1 24	$747M	$300M	$1.0B
Q2 24	$972M	$252M	$1.2B
Q3 24	$675M	$255M	$930M
Q4 24	$943M	$195M	$1.1B
Q1 25	$1.0B	$224M	$1.3B
Q2 25	$1.2B	$218M	$1.4B
Q3 25	$1.3B	$228M	$1.5B
Q4 25	$1.3B	$249M	$1.6B

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	194M	+4.5%
Q2 23	195M	+0.3%
Q3 23	191M	-2.0%
Q4 23	192M	+0.3%
Q1 24	199M	+3.9%
Q2 24	201M	+0.6%
Q3 24	197M	-1.7%
Q4 24	197M	-0.3%
Q1 25	196M	-0.1%
Q2 25	197M	+0.1%
Q3 25	192M	-2.3%
Q4 25	197M	+2.8%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$446K	2K
FY 15	$412K	2K
FY 16	$487K	2K
FY 17	$509K	3K
FY 18	$523K	3K
FY 19	$568K	3K
FY 20	$608K	3K
FY 21	$606K	3K
FY 22	$680K	3K
FY 23	$711K	3K
FY 24	$939K	3K
FY 25	$16K	200K

BMRN (BioMarin Pharmaceutical Inc.) Stock Financials & Earnings | Market Cap Arena